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Background

Neuroendocrine tumors are a rare finding in the gallbladder. The incidence of this entity in
the gallbladder is roughly 1.13 cases per 100,000 in the US, with a steady increase in the last
decade. Gallbladder neuroendocrine tumors are generally asymptomatic; the majority of
cases have been reported as incidental findings in specimens, resected due to secondary
symptomatology, such as chronic cholecystitis. Treatment strategies are limited, in part
due to the often advanced stage in which this disease presents. Furthermore, there is a
restricted utility of diagnostic tools for early detection; these factors contribute to the poor
prognosis of this disease process.
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Case Summary

We describe a case of a gallbladder carcinoid tumor, incidentally found in a 78-year-old male
patient who presented to the emergency room complaining of chronic intermittent right
upper quadrant pain, accompanied by nausea and vomiting. A positive murphy sign was
elicited on physical examination, which was otherwise unremarkable. An abdominal ultrasound showed an otherwise normal-appearing gallbladder except for a “floating polyp” with
no suspicious radiologic features. A diagnosis of chronic cholecystitis was presumed, and
the patient was taken to the operative room for laparoscopic cholecystectomy. Microscopic
evaluation of the gallbladder specimen yielded a diagnosis of a well-differentiated neuroendocrine tumor and complex cholesterol polyps, in a setting of chronic cholecystitis.

Conclusions

Neuroendocrine tumors of the gallbladder, a rare entity, are generally asymptomatic, with
most cases diagnosed incidentally in gallbladder specimen resected for reasons other
than suspected malignancy. Chronic inflammatory processes are seen to be related to the
development of metaplasia and possibly the development of tumors of the neuroendocrine
lineage. Based on a review of literature, we have found that no specific treatment approach,
beyond surgical resection, is in place to manage patients with this condition. Formation of
an expert committee to review and discuss guidelines for appropriate clinical monitoring, as
well as consideration of a multi-site prospective registry is suggested.
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Introduction

More than ten different types of neuroendocrine cells are present throughout the gastrointestinal (GI) tract. Among these various cell
types, enterochromaffin cells are thought to
be the precursor of neuroendocrine tumors
(NETs). These highly specialized cells, despite
their widespread distribution in the GI tract,
are usually not present in the gallbladder.1 NETs

are routinely diagnosed in the gastrointestinal
and respiratory tract and are considered a rare
finding in the gallbladder, with an incidence
of approximately 1.13 cases per 100,000.2 The
mechanism for neoplastic transformation is
still not well understood; however, it is hypothesized that there is a correlation between
metaplasia and NETs in long-standing inflammatory processes such as chronic cholecysti
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and essential hypertension, for which he was
getting the appropriate treatment. On further
assessment, the abdominal ultrasound showed
an otherwise normal-appearing gallbladder,
except for a “floating polyp” with no suspicious
radiologic features. Laboratory analysis showed
mildly elevated AST and BUN, and decreased
GFR, but was otherwise unremarkable. A clinical diagnosis of chronic acalculous cholecystitis
and gallbladder polyp was made. A decision
was taken to proceed with surgical intervention, and laparoscopic cholecystectomy was
performed.
Figure 1. Complex cholesterol polyp. H&E (10X
original magnification) Image provided by the
authors.
tis.3, 4 (Figures 1 and 2) NETs can arise anywhere
within the gallbladder, with no tendency for a
specific anatomical site. Clinical manifestation
is non-specific and is usually related to symptoms of a secondary pathologic process such
as chronic cholecystitis.5 Classification is based
on histological features and mitotic activity
of tumor cells, and is grouped in two broad
categories: well-differentiated (with better
prognosis in most cases), and poorly differentiated (characteristically aggressive and with
poor prognosis). The well-differentiated type
accounts for a minority of cases with a slight
incidental rise in recent years due to the improvement of diagnostic methods, as well as
more awareness among pathologists regarding
this lesion. Prognosis is based on factors like
tumor size, the grade of differentiation, presence of angio-invasion and local spread to adjacent structures (liver) or regional lymph nodes.5
There is no standardization in the management
of these cases, with therapeutic decisions
taken based upon personal experience, as well
as the general approach to gallbladder tumors
others than NETs.

Histological examination of the gallbladder
specimen showed a 2-millimeter lesion, located
within the gallbladder wall, about 1 millimeter
from the serosa surface. Microscopic evaluation
revealed a round-to-oval, well-circumscribed
proliferation of monotonous neoplastic cells
arranged in cords and nests. The neoplastic
cells had a central ovoid nucleus, with stippled
chromatin and inconspicuous nucleoli. The
immunohistochemical profile was relatively uniform, with immune-reactivity for chromogranin
and synaptophysin, and an absence of subtentacular cells (S100 negative). These classical
morphological features, along with the uniform
staining pattern, confirmed the neuroendocrine
lineage of the lesional cells.
The final diagnosis was rendered as neuroendocrine tumor of the gallbladder, in the settings
of chronic cholecystitis and complex cholesterol
polyps. After surgical intervention, the patient

Case Presentation

We describe a case of a gallbladder carcinoid
tumor, incidentally found in a 78-year-old male
patient who came to the emergency room (ER)
complaining of chronic, intermittent, right
upper-quadrant pain, accompanied by nausea and vomiting. Physical examination was
non-contributory, except for a positive murphy
sign. Medical history was significant for gout
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Figure 2. Gallbladder mucosal polyp with osseous metaplasia, in a setting of chronic cholecystitis. H&E (10X original magnification) Image
provided by the authors.
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was discharged with instructions to follow-up
on the pathology results in the outpatient
setting. After a negative PET-CT and almost
one year follow up, he has been declared free of
disease.

Discussion

Neuroendocrine tumor of the gallbladder is an
extremely rare diagnosis. The clinical presentation is non-specific and overlaps with other
types of gallbladder malignancies, especially
adenocarcinomas. In recent years, the incidence
of this pathologic process has been increasing
at a steady rate. This may be explained by improved sensitivity of the diagnostic radiological
tools and increased awareness among pathologists. Radiologic findings, such as a heterogeneous or hypo-attenuating mass (which
shows variable degrees of enhancement),
circumferential homogenous thickening or an
intraluminal polypoid mass, are not reliable
in distinguishing NETs from other forms of
gallbladder tumors. In advanced cases, direct
liver involvement (present in up to 44% of the
cases) by the tumor can be evident in the liver
segments contiguous with the gallbladder bed
(segments 4 and 5). Metastases can occur even
in microscopic lesions and appear to have no
relationship with tumor size, grade of differentiation and proliferation indices. The most
common site for metastases is the hilar lymph
nodes and liver (segments other than 4 and 5),
with about 80% of cases with metastases

Figure 3. Focal cellular proliferation of cells
with salt-and-pepper chromatin forming nests
and cords in the gallbladder wall, infiltrating
muscularis mucosa and approaching serosa
surface H&E. (4x original magnification) Image
provided by the authors.

Figure 4. High power image of the neoplastic
cells showing salt and pepper chromatin. No
mitotic activity was identified. Neoplastic cells
are organized mainly in nest-like structures.
H&E (40X original magnification) Image provided by the authors.
presenting with an enlarged lymph node on CT
images.6, 7
Histologically, gallbladder NETs resemble their
homologous counterparts throughout the
gastrointestinal tract, with the cytological
architecture depending on the grade of differentiation. The well-differentiated lesions are
generally composed of small, uniform cells with
low variability in size and shape, organized in
nests, cords, trabecular and glandular patterns.
(Figures 3 and 4) Tumor cells in the poorly
differentiated type are large and pleomorphic
with prominent nucleoli and a variable amount
of cytoplasm. Necrosis and mitotic activity are
salient findings in the latter. Though an independent factor, metastases and angio-invasion
are more common in poorly differentiated
cases.
The World Health Organization (WHO) classifies neuroendocrine neoplasias into two main
subcategories based on grade of differentiation: well-differentiated type and poorly differentiated type. The well-differentiated type is
further classified into grades (G1, G2, and G3)
based on mitotic rate and proliferation indices.
The low-grade subtype (G1) typically has a low
mitotic rate and proliferation index (Figure 5),
less than 2 mitosis/high-power field (HPF), and
less than 2 percent proliferation rate, respectively. Historically, this was considered a benign
condition with uncertain malignant potential;
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Figure 5. Immunohistochemistry: Ki67 demonstrating a proliferative index of about 1%. (40x
original magnification) Image provided by the
authors.
however, its metastatic potential is now well
recognized, even in microscopic lesions. The
intermediate grade (G2) in this category is defined by a mitotic rate between 2-20/HPF and
a proliferation rate that does not surpass 20%.
The grade 3 (G3) or high-grade type has some
overlapping features with the poorly differentiated neuroendocrine carcinoma (NEC), such
as a Ki67 more than 20%, but typically less than
50% and more than 20 mitotic figures per 10
HPF; however, the clinical and genetic differences help make them distinguishable.8 Mutations in the MEN1, DAXX and ATRX genes define the well-differentiated NETs, while NECs
usually have TP53 or RB1 gene mutations.
The diagnosis of a neuroendocrine tumor of
the gallbladder is exclusively made by histologic
examination. Immunohistochemistry profile for
NETs has some variabilities and these tumors
can be immunoreactive to a variety of immuno-stains, including synaptophysin (Figure 6),
chromogranin (Figure 7), CD56, neuron-specific
enolase (NSE), pan-cytokeratin (AE1/AE3) and
CK7. Synaptophysin results in positive staining
in up to 90% of the cases, while chromogranin
results in positive staining in up to 85% of the
cases. The use of these two neuroendocrine
markers in combination often yields positive
results in up to 95% of cases.
The differential diagnosis for NETs of the gallbladder can be very broad, depending upon the
grade of differentiation and the architectural
patterns of the lesion. Gangliocytic paragangliomas (GP) are a rare entity with multiple
152

overlapping structural, cytologic and immunohistochemical features similar to NETs. The
epithelioid cell types are typically arranged in
nests, trabeculae or papillary structures. Immunohistochemically, these lesions show reactivity
to S-100 and NSE, the ganglion cells are positive for synaptophysin and up to 50% positivity for cytokeratin, making the differential
diagnosis even more difficult. Glomus tumor
is another entity that represents a diagnostic
challenge in the differential diagnosis of NETs.
These tumors are multinodular with strands of
smooth muscle dissecting in between the nodules. The nodules are composed of solid sheets
of cells that typically surround a blood vessel.
Cells comprising these nodules are round with
a sharply defined border and evenly distributed
chromatin. On immunohistochemistry, these
cells are positive for calponin and smooth muscle actin, but typically lack immunoreactivity for
neuroendocrine markers.
Treatment options for NETs of the gallbladder are limited by the advanced stage in which
almost all cases present, and the lack of data
that supports a particular approach. Current
practices are based on personal experiences
and the consensus from other types of gallbladder tumors. Surgical resection (when possible) with gallbladder bed cauterization is seen
to be adequate for low-grade tumors without
serosa or contiguous involvement of liver parenchyma. In advanced cases with metastases
to liver parenchyma (contiguous spread or distant metastases) or regional lymph nodes, surgical resection of the gallbladder (if possible)
followed by chemotherapy is seen to be the

Figure 6. Immunohistochemistry: Strong immunoreactivity for synaptophysin. (20x original
magnification) Image provided by the authors.
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to manage patients with this disease process.
Multi-center studies could help to further elucidate the pathogenesis, behavior and treatment
strategies for neuroendocrine neoplasia of the
gallbladder.
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Figure 7. Immunohistochemistry: Diffused immunoreactivity for chromogranin. (20X original
magnification) Image provided by the authors.
best approach; albeit there is lack of sufficient
statistical evidence to support this appraoch.5, 9
There are multiple chemotherapy agents used
in the treatment of tumors of neuroendocrine
origin; among them, the most frequently used
are cisplatin and carboplatin. The combination of chemotherapeutic agents are more
often used than a single agent. Cisplatin and
carboplatin are combined with gemcitabine
and etoposide, with some studies reporting a
tumor regression of up to 67% using this strategy.
The prognosis of this disease is highly variable,
depending upon the stage in which the patient
presents, the degree of differentiation and
proliferation indices of the tumor. Typically,
well-differentiated lesions, confined to the
gallbladder’s wall and without systemic metastasis, have an excellent prognosis. However, the
poorly differentiated type typically presents in
more advanced stages, with local spread and
systemic metastasis. These cases count for the
majority of gallbladder NET-related fatalities.
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